CALCIVIS LIMITED

• ⚠

  Material uncertainty over going concern

  The directors acknowledge that a material uncertainty related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern and, therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. This is on the basis that in order for the company to remain in a positive cash position, further funding will be required to be obtained within the period covered by managements forecasts.

• ◆

  3 officer resignations in last 12 months

  Multiple officers have left the board recently — see the People section for who.

Values shown as filed in the company's annual accounts. — indicates the figure wasn't present under that line item in that period. About these numbers

Margins divide P&L lines by turnover. Gearing is liabilities over total assets. Current ratio is current assets over creditors falling due within one year. Interest cover is operating profit over absolute finance costs. Sector-distribution context coming next.

Accounting basis

UK-adopted International Accounting Standards

Reporting scope

Standalone (parent only)

Auditor

Johnston Carmichael LLP

Audit opinion

Unqualified (clean)

Going concern

Material uncertainty disclosed

“The directors acknowledge that a material uncertainty related to events or conditions that may cast significant doubt on the entity's ability to continue as a going concern and, therefore, that it may be unable to realize its assets and discharge its liabilities in the normal course of business. This is on the basis that in order for the company to remain in a positive cash position, further funding will be required to be obtained within the period covered by managements forecasts.”

Group structure

1. CALCIVIS LIMITED · parent
   1. Calcivis Inc 100% · Wilmington, Delaware · Development of novel dental imaging technologies.

Significant events

• “The company received notification from the US Food and Drug Administration (FDA) in March 2023 that they had completed its review of the premarket approval application (PMA) for the Calcivis Imaging System, which was deemed approvable. This was seen as a major milestone by investors and is an important factor in the ability of the company to raise future finance. The company appointed Greg Sheehan as its new Chief Executive Officer in April 2025.”

Auditor, going-concern and subsidiary information is drawn from the narrative of the latest annual accounts. About these numbers

Filings

10

last 12 months

Capital events

0

last 24 months

Officers appointed

1

last 12 months

Officers resigned

3

last 12 months

Direct counts from the register. No score, no rating — see the Filing timeline for the underlying events.

• Turnover

  +3,994.4%

  £4,500 → £184,246

• Cash

  +362.3%

  £467,839 → £2,162,982

• Net assets

  +394%

  -£1,182,506 → £3,476,403

• Employees

  +28.6%

  7 → 9

• Operating profit

  -13.6%

  -£2,076,661 → -£2,359,272

• Profit before tax

  -3.3%

  -£2,234,968 → -£2,309,383

• Wages

  +15.3%

  £656,063 → £756,115

Each % is (latest − prior) ÷ |prior| for the line item as filed. The comparison is only shown when the latest and prior accounts cover broadly equal-length periods — short or long stubs (typical around incorporation or a year-end change) are suppressed rather than misrepresented. Lines a company doesn't report are omitted. About these numbers